PharmaTher Holdings Ltd.
PHRRF · Other OTC · USD
0,041USD
+0,006 (+17,14 %)Stand 9. Nov., 21:00
Kennzahlen
- Eröffnung
- 0,0409
- Vortag
- 0,035
- Tagesspanne
- 0,0409 – 0,041
- 52 Wochen
- 0,032 – 0,121
- Volumen
- 1825
- Ø Volumen
- 124.223
- Börsenwert
- 3,73 Mio. $
- KGV
- -13,1
- Gewinn je Aktie (TTM)
- -0,00
- Dividendenrendite
- 0,0 %
- Beta
- 2,4
- Nächste Zahlen
- 22. Jan. 2027
Finanzen
| CAD | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Umsatz | 0 | 0 | 0 | 0 | 0 |
| Herstellungskosten | 0 | 0 | 0 | 1422 | 1777 |
| Bruttogewinn | 0 | 0 | 0 | −1422 | −1777 |
| Forschung und Entwicklung | 149.935 | 581.560 | 2,14 Mio. | 3,02 Mio. | 2,61 Mio. |
| Vertrieb und Verwaltung | 706.261 | 942.077 | 904.367 | 941.721 | 1,36 Mio. |
| Operatives Ergebnis | −856.197 | −1,52 Mio. | −3,04 Mio. | −3,96 Mio. | −3,97 Mio. |
| EBITDA | −856.197 | −1,52 Mio. | −3,04 Mio. | −3,96 Mio. | −3,96 Mio. |
| Nettogewinn | −617.831 | −1,53 Mio. | −3,12 Mio. | −6,42 Mio. | −4,01 Mio. |
| Gewinn je Aktie (verwässert) | -0,01 | -0,02 | -0,04 | -0,07 | -0,05 |
Bewertung
Letzte 12 Monate
- KGV
- -13,1
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 12,8
- PEG
- -0,1
- Bruttomarge
- 0,0 %
- Operative Marge
- 0,0 %
- Nettomarge
- 0,0 %
- Verschuldungsgrad
- 0,0
- EV/EBITDA
- -7,8
- Eigenkapitalrendite
- −75,6 %
- Kapitalrendite (ROIC)
- −169,5 %
- Free-Cashflow-Rendite
- −9,7 %
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Bruttomarge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Operative Marge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Nettomarge | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| KGV | -9,6 | -12,1 | -6,1 | -1,5 | -2,8 |
| Kurs-Umsatz-Verhältnis | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Kurs-Buchwert-Verhältnis | 9,7 | 16,3 | 8,2 | 1,8 | 0,9 |
| Verschuldungsgrad | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
| Liquidität 3. Grades | 1,8 | 3,1 | 9,2 | 7,1 | 36,8 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 5,23 Mio. | 14,9 Mio. | 17 Mio. | 4,01 Mio. | 1,91 Mio. |
| EV/EBITDA | -6,1 | -9,8 | -5,6 | -1,0 | -0,5 |
| Eigenkapitalrendite | −100,7 % | −156,8 % | −133,3 % | −118,4 % | −33,9 % |
| Kapitalrendite (ROIC) | −139,6 % | −156,5 % | −130,3 % | −73,1 % | −31,8 % |
| Free-Cashflow-Rendite | −8,3 % | −7,6 % | −18,4 % | −32,6 % | −31,7 % |
Wachstum
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Umsatz | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Bruttogewinn | 0,0 % | 0,0 % | +100,0 % | +20,0 % | −400,6 % |
| Operatives Ergebnis | +43,8 % | +49,9 % | +23,1 % | +0,2 % | −63,3 % |
| Nettogewinn | +59,5 % | +51,0 % | +51,4 % | −60,0 % | −250,5 % |
| Gewinn je Aktie | +66,0 % | +43,3 % | +51,5 % | −47,4 % | −235,7 % |
| Freier Cashflow | +59,4 % | +65,6 % | −8,9 % | +7,9 % | −482,5 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2027 | |
|---|---|
| Umsatz (Ø) | 81,67 Mio. |
| Umsatz (Tief – Hoch) | 81,67 Mio. – 81,67 Mio. |
| Gewinn je Aktie (Ø) | -0,04 |
| Gewinn je Aktie (Tief – Hoch) | -0,04 – -0,04 |
| Analysten | 1 |
Quartalszahlen
Nächste Zahlen: 22. Jan. 2027| Okt. 2026 | Jan. 2026 | Okt. 2025 | Apr. 2025 | Jan. 2025 | Sept. 2024 | Juli 2024 | Apr. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | -0,01 | -0,03 | – | – | – | -0,02 | -0,02 | -0,02 |
| Gewinn je Aktie · Tatsächlich | -0,00 | -0,00 | -0,00 | -0,00 | -0,00 | -0,00 | -0,00 | -0,00 |
| Abweichung | +79,11 % | +91,22 % | – | – | – | +80,45 % | +81,36 % | +81,44 % |
| Umsatz · Tatsächlich | – | – | – | – | – | – | – | – |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
BETRFBetterLife Pharma Inc.0,14−6,67 %
BIXTBioxytran, Inc.0,0208−9,96 %
CHMMFChimeric Therapeutics Limited0,100,00 %
CUBTCurative Biotechnology, Inc.0,71−14,46 %
GLWLFGlow Lifetech Corp.0,0286−3,19 %
LIANYLianMedical0,046+17,95 %
MYNDFMYND Life Sciences Inc.0,00810,00 %
NSHSFNanoSphere Health Sciences Inc.0,00670,00 %
Über das Unternehmen
PharmaTher Holdings Ltd. is a biotechnology firm in the clinical stage, specializing in psychedelic treatments. Its primary objective is to investigate, develop, and bring to market innovative applications, drug forms, and administration techniques for psychedelics, addressing conditions such as mental health issues, neurological diseases, and chronic pain. Among its pipeline of products, the company is advancing an intravenous ketamine injection, which is currently undergoing Phase II and III clinical trials for its potential use in treating Parkinson's disease, providing anesthesia and sedation, and managing amyotrophic lateral sclerosis (ALS). Additionally, PharmaTher is developing a Ketamine Patch, in Phase I and II trials for conditions like depression, various mental health disorders, complex regional pain syndrome (CRPS), and other pain-related ailments. A Ketamine Pump is also part of their development, currently in Phase II clinical trials for applications in mental health, pain management, and surgical/procedural settings. Furthermore, the company is actively working on PHARMAPATCH, a microneedle patch designed for the transdermal delivery of psychedelic compounds. PharmaTher has established several strategic partnerships to further its development. These include collaborations with LTS Lohmann Therapie-Systeme AG for a ketamine microneedle patch, Alcami Corporation for ketamine injectables and infusions, and BioRAE, Inc. for ketamine pump development. They are also working with Revive Therapeutics Ltd. on a psilocybin microneedle patch and with Gesval S.A. on a patented continuous-flow process for producing ketamine and its analogs. The company is also developing its own proprietary wearable ketamine delivery system, specifically tailored for mental health, neurological, and pain disorders. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Führung
- Fabio ChianelliFounder, Chairman & Chief Executive Officer
- Carmelo Marrelli ACISChief Financial Officer
- Andrew ToddCorporate Secretary
- CEO
- Fabio Chianelli
- Mitarbeitende
- 5
- Hauptsitz
- Toronto, ON, CA
- Sektor
- Healthcare
- Branche
- Biotechnology
- Börsengang
- 8. Jan. 2021
- Website
- pharmather.com
Nachrichten
- Newsfile Corp · 29. Okt., 10:01PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
- Newsfile Corp · 28. Okt., 8:00PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
- Newsfile Corp · 5. Okt., 8:00PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
- Newsfile Corp · 1. Okt., 8:00PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
- Defense World · 29. Sept., 6:20PharmaTher Holdings Ltd. (OTCMKTS:PHRRF) Shares Shorted: Short Interest Up 98.5% in September
- Newsfile Corp · 11. Aug., 8:00PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.